A Phase 1 interventional study of LY2835219 and Rifampin in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-07.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this two-period study is to compare how much of the study drug gets into the blood stream when it is given as a single oral dose and when it is given as a single oral dose in combination with rifampin (a Food and Drug Administration [FDA] approved antibiotic that is used to treat tuberculosis, a bacterial infection that mainly affects the lungs, and other infections). Each participant will complete both study periods.
The study will last about 34 days. Screening is required within 28 days before study drug is given.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral dose of LY2835219
Drug: LY2835219
Single oral dose of LY2835219 with rifampin orally, once daily for 14 days
Drug: LY2835219 · Drug: Rifampin
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2835219
Time frame: Period 1: Day 1- Predose,1, 2, 4, 6, 8, 10 hours, Days 2-9: 24, 48, 72, 96, 120, 144, 168, and 192 hours; Period 2: Day 7- Predose,1, 2, 4, 6, 8, 10 hours, Days 8-15: 24, 48, 72, 96, 120, 144, 168, 192 hours
PK: Area Under the Concentration Time Curve AUC(0-∞) of LY2835219
Time frame: Period 1: Day 1- Predose,1, 2, 4, 6, 8, 10 hours, Days 2-9: 24, 48, 72, 96, 120, 144, 168, and 192 hours; Period 2: Day 7- Predose,1, 2, 4, 6, 8, 10 hours, Days 8-15: 24, 48, 72, 96, 120, 144, 168, 192 hours
| Milestone | LY2835219 Then LY2835219 + Rifampin |
|---|---|
| Started | 24 |
| Received at least 1 dose of ly2835219 | 24 |
| Completed | 23 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
| Milestone | LY2835219 Then LY2835219 + Rifampin |
|---|---|
| Started | 23 |
| Received at least 1 dose of rifampin | 23 |
| Completed | 23 |
| Not completed | 0 |
| Milestone | LY2835219 Then LY2835219 + Rifampin |
|---|---|
| Started | 23 |
| Received ly2835219 + rifampin | 23 |
| Completed | 22 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
| nanogram per milliliter (ng/ml) | 200 mg LY2835219 | 200 mg LY2835219 + 600 mg Rifampin |
|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2835219 | 134 ± 45 | 10.5 ± 58 |
| nanogram x hour per mL (ng x h/mL) | 200 mg LY2835219 | 200 mg LY2835219 + 600 mg Rifampin |
|---|---|---|
| PK: Area Under the Concentration Time Curve AUC(0-∞) of LY2835219 | 4570 ± 53 | 229 ± 48 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LY2835219 | — | 0/24 (0%) | 8/24 (33.3%) |
| Rifampin | — | 0/23 (0%) | 2/23 (8.7%) |
| LY2835219 + Rifampin | — | 1/23 (4.3%) | 4/23 (17.4%) |
| Event | LY2835219 | Rifampin | LY2835219 + Rifampin |
|---|---|---|---|
| SyncopeNervous system disorders | 0/24 | 0/23 | 1/23 |
| Event | LY2835219 | Rifampin | LY2835219 + Rifampin |
|---|---|---|---|
| NauseaGastrointestinal disorders | 1/24 | 1/23 | 3/23 |
| Upper respiratory tract infectionInfections and infestations | 3/24 | 1/23 | 0/23 |
| HeadacheNervous system disorders | 1/24 | 0/23 | 2/23 |
| DiarrhoeaGastrointestinal disorders | 2/24 | 1/23 | 0/23 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/24 | 0/23 | 0/23 |
| Age, Continuous(years) | LY2835219 Alone, Then Rifampin, Then LY2835219 + Rifampin |
|---|---|
| Mean | 58.8 ± 7.4 |
| Sex: Female, Male(Participants) | LY2835219 Alone, Then Rifampin, Then LY2835219 + Rifampin |
|---|---|
| Female | 21 |
| Male | 3 |
| Race (NIH/OMB)(Participants) | LY2835219 Alone, Then Rifampin, Then LY2835219 + Rifampin |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 6 |
| White | 15 |
| More than one race | 3 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | LY2835219 Alone, Then Rifampin, Then LY2835219 + Rifampin |
|---|---|
| United States | 24 |
The record gives a start of Oct 2014, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2018, 3 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abemaciclib